Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Manuel M. Hidalgo, Ron Epelbaum, Valeriya Semenisty, Ravit Geva, Talia Golan, Erkut Hasan Borazanci, Salomon M. Stemmer, Mitesh J. Borad, Joon Oh Park, Katrina Pedersen, Brian M. Wolpin, Robert A. Ramirez, Carlos Becerra, Stephen Michael Shaw, Galia Oberkovitz, Ella Sorani, Tzipora M Lustig, Abi Vainstein Haras, Amnon Peled, Daniel D. Von Hoff
Institutions: Beth Israel Deaconess Medical Center, Rambam Health Care Campus, Tel Aviv Sourasky Medical Center, Sheba Medical Center, HonorHealth, Rabin Medical Center, Mayo Clinic in Arizona, Samsung Medical Center, Sungkyunkwan University, Mayo Clinic, Dana-Farber Cancer Institute, Louisiana State University Health Sciences Center New Orleans, BioLineRx Ltd. (Israel), Hebrew University of Jerusalem, Translational Genomics Research Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4251423547